TG Therapeutics
TGTX
NASDAQ
IPO1995
about TGTX
TG Therapeutics is a biopharmaceutical company focused on developing innovative treatments for cancers such as lymphoma and leukemia, immune-mediated diseases like psoriasis, and other conditions, with key products including umilast, an oral disease-modifying therapy in late-stage development.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $33.49 | $34.24 | $33.16 | $5.29B | 1.54M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| +$0.19 | 130.77 | 39.16 | 24.69% | 19.97% | 0% |